News ListWednesday March 30, 2005 Ipsogen to present breast cancer program results at the upcoming AACR annual meeting.Marseille, France, March 30, 2005 – The abstract titled "Utilisation of microarray technology to refine molecular classes and improve clinical management of breast cancer," is available on the AACR website ( Read... Category: Breast Cancer
 Tuesday March 15, 2005 Ipsogen announces the recent opening of additional offices in the USA, further expanding its ability to deliver a growing range of oncodiagnostic products worldwideMarseille, France, March 15, 2005 – Located in Windsor Connecticut, the formation of Ipsogen Inc. provides the company with expanded direct sales capabilities and effective local product support in North America. Ipsogen Inc.... Category: Corporate
 Wednesday February 09, 2005 Ipsogen is formally accepted as a participant of the European LeukemiaNet.Marseille, France, 9 “Ipsogen is privileged to have been accepted as a participant of this important European network. With Ipsogen’s focus and positioning as a leader in providing standardised validated IVD assays to clinical... Category: Leukemia
 Wednesday November 17, 2004 Ipsogen and Genaissance Pharmaceuticals, Inc. announce a co-marketing agreementMarseille, France and New Haven, CT , November 17, 2004 - Privately held Ipsogen and Genaissance Pharmaceuticals, Inc. (NASDAQ: GNSC) announced today that the two companies had signed a co-marketing agreement, under which the... Category: Corporate
Wednesday October 27, 2004 Ipsogen signs an agreement with the Cleveland Clinic to identify molecular markers in early stage breast cancer.Marseille, France, Wednesday, 27 October 2004 - Ipsogen announced today that it has signed an agreement with The Cleveland Clinic and Dr. Richard Crownover (Cleveland, USA) to identify molecular markers in early stage breast... Category: Breast Cancer
Friday July 23, 2004 Ipsogen signs an agreement to become an authorised service provider for Affymetrix technologies
“Adding the AFFYMETRIX Platform to our technology portfolio strengthens our ability to meet the needs of our academic and industry partners to optimize drug development and personalise patient care in oncology. GeneChip®... Category: Breast Cancer
Thursday May 06, 2004 Ipsogen announces selection by the French network of anti-cancer centres to investigate gene expression in breast tumours treated with anthracycline therapy.
“This agreement with FNCLCC is an important critical step in applying genomic tools to improve standard chemotherapy regimen in breast cancer. This large scale genomic study will provide homogeneous treatments and monitoring... Category: Breast Cancer
Monday February 16, 2004 Ipsogen announces CE marking of its M-bcr FusionQuant™ assay.Marseille, France, February 16, 2004 - "Our M-bcr FusionQuant product is the first commercially available IVD assay in Europe for the quantification of the BCR-ABL gene, an acquired chromosomal abnormality occurring in... Category: Leukemia
Saturday February 14, 2004 Ipsogen announces that the FDA / OPD qualified the MLL FusionChip™ for Humanitarian Use Device (HUD) designationIpsogen The MLL FusionChip ™ is an in vitro molecular diagnostic device utilizing an innovative biochip technology aimed at providing qualitative information on the gene fusion events between the MLL gene and its... Category: Leukemia
Friday February 06, 2004 Ipsogen announces an exclusive license in Europe from Genzyme Corporation to use the WT1 gene as a biomarker in acute LeukemiaMarseille, France, 2 “Several studies have shown that blood levels of Wilm’s tumour (WT1) can be used in Acute Myeloid Leukaemia (AML) at diagnosis to predict disease aggressiveness, determine patient response to treatment, and... Category: Leukemia
|
|
